Correction
Rofecoxib, Merck, and the FDA
N Engl J Med 2005; 352:1163March 17, 2005
- Article
Rofecoxib, Merck, and the FDA (Correspondence, N Engl J Med 2004:351;2875 - 2878) . In the letter by Topol, in Table 1 on page 2878, the 95 percent confidence interval for the number of total deaths and cardiovascular events in study group 090 should have been “1.2–46.3,” rather than “1.2–146.3,” as printed.
